Intuitive Surgical, Inc. $ISRG Position Increased by Platform Technology Partners

Platform Technology Partners raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 126.9% in the third quarter, HoldingsChannel.com reports. The fund owned 4,889 shares of the medical equipment provider’s stock after purchasing an additional 2,734 shares during the quarter. Platform Technology Partners’ holdings in Intuitive Surgical were worth $1,988,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Main Street Group LTD acquired a new position in shares of Intuitive Surgical during the 1st quarter worth about $30,000. North Point Portfolio Managers Corp OH acquired a new stake in Intuitive Surgical in the 3rd quarter valued at about $27,000. John Boyer Inc. acquired a new stake in Intuitive Surgical in the 3rd quarter valued at about $27,000. Compass Wealth Management LLC acquired a new stake in Intuitive Surgical in the 3rd quarter valued at about $29,000. Finally, Evergreen Advisors LLC bought a new position in Intuitive Surgical during the first quarter worth about $35,000. Institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. BTIG Research reissued a “buy” rating and set a $454.00 price target on shares of Intuitive Surgical in a research report on Wednesday, October 21st. HSBC lowered Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 price objective on the stock. in a research note on Thursday, July 30th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Intuitive Surgical in a research report on Wednesday, August 12th. Oppenheimer reiterated an “outperform” rating and set a $500.00 target price on shares of Intuitive Surgical in a research note on Wednesday, October 21st. Finally, Royal Bank Of Canada reduced their target price on Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating for the company in a research note on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $493.54.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $468.52 on Friday. The company has a market cap of $162.41 billion, a P/E ratio of 56.65, a P/E/G ratio of 3.32 and a beta of 1.45. The firm’s fifty day moving average price is $408.22 and its two-hundred day moving average price is $432.27. Intuitive Surgical, Inc. has a one year low of $328.57 and a one year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.35. The company had revenue of $3.05 billion during the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. Intuitive Surgical’s quarterly revenue was up 21.7% compared to the same quarter last year. During the same quarter last year, the company posted $2.40 EPS. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Amy L. Ladd sold 400 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total transaction of $151,600.00. Following the completion of the sale, the director directly owned 251 shares in the company, valued at $95,129. This trade represents a 61.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary S. Guthart sold 20,095 shares of the firm’s stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $451.61, for a total transaction of $9,075,102.95. Following the sale, the director owned 1,204,530 shares of the company’s stock, valued at $543,977,793.30. This trade represents a 1.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 49,928 shares of company stock worth $21,917,367 in the last 90 days. Corporate insiders own 0.60% of the company’s stock.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Da Vinci system placements rose 28% year over year to 546 in Q3 2026, while net placements increased 40%, pointing to continued demand for Intuitive Surgical’s robotic-surgery systems and expansion of its installed base. Article: ISRG System Placements Rise 28%
• Neutral Sentiment: The placements increase may reflect multisystem orders and upgrades, rather than a broad-based upswing in hospital capital-equipment budgets. That leaves open whether the strong pace can be sustained. Article: ISRG System Placements Rise 28%: Is Capital Equipment Demand Rising?
• Negative Sentiment: Two directors disclosed share sales: Gary Guthart sold 10,000 shares (0.83% of his position), and Craig Barratt sold 1,150 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which may temper—but not eliminate—their significance as a sentiment overhang. SEC filing: Gary Guthart transaction SEC filing: Craig Barratt transaction

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.